Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
- DOI
- 10.1111/jdi.13959
- Published
- 2023 Mar
- Container
- Journal of diabetes investigation
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/jdi.13959,
title = {Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.},
author = {Kim DJ and Sheu WH and Chung WJ and Yabe D and Ha KH and Nangaku M and Tan EC and Node K and Yasui A and Lei W and Lee S and Saarelainen L and Deruaz-Luyet A and Kyaw MH and Seino Y and EMPRISE East Asia Study Group},
year = {2023},
journal = {Journal of diabetes investigation},
doi = {10.1111/jdi.13959},
url = {https://doi.org/10.1111/jdi.13959}
}RIS
TY - JOUR TI - Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study. AU - Kim DJ AU - Sheu WH AU - Chung WJ AU - Yabe D AU - Ha KH AU - Nangaku M AU - Tan EC AU - Node K AU - Yasui A AU - Lei W AU - Lee S AU - Saarelainen L AU - Deruaz-Luyet A AU - Kyaw MH AU - Seino Y AU - EMPRISE East Asia Study Group PY - 2023 JO - Journal of diabetes investigation DO - 10.1111/jdi.13959 UR - https://doi.org/10.1111/jdi.13959 ER -
APA
DJ, K., WH, S., WJ, C., D, Y., KH, H., M, N., EC, T., K, N., A, Y., W, L., S, L., L, S., A, D., MH, K., Y, S., & Group, E. E. A. S. (2023). Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.. Journal of diabetes investigation. https://doi.org/10.1111/jdi.13959
Source records
- pubmed · retrieved 2026-09-27T06:21:41.190Z